Natus Medical shares were up over 5% after the company said it expects FY17 sales between $505 million and $510 million, above the CapIQ mean for $438.5 million. Non-GAAP EPS is seen between $1.80 to $1.85, in line with estimates for $1.81.
Q1 sales are expected between $122 million to $124 million, topping forecasts for $104.9 million. The company sees non-GAAP EPS between $0.32 and $0.34, below expectations for $0.41.
Q416 sales is seen between $107.5 million and $108 million, in line with the Street’s $107.6 million and compared with prior guidance for $107 million to $109 million.
FY16 sales are forecast between $381.5 million and $382 million compared to prior guidance of $381.2 million to $383.2 million and Wall Street’s estimates for $381.9 million.